News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
94,253 Results
Type
Article (5066)
Company Profile (4)
Press Release (89183)
Multimedia
Podcasts (27)
Webinars (4)
Section
Business (30253)
Career Advice (112)
Deals (4827)
Drug Delivery (21)
Drug Development (10523)
Employer Resources (8)
FDA (2649)
Job Trends (2316)
News (46085)
Policy (6406)
Tag
2027 Genetown Standard (2)
2027 Pharm Country Standard (1)
Academia (224)
Accelerated approval (13)
ADA (4)
Adcomms (1)
Allergies (43)
Alliances (6230)
ALS (68)
Alzheimer's disease (195)
Antibody-drug conjugate (ADC) (85)
Approvals (2924)
Artificial intelligence (76)
ASCO (36)
Autoimmune disease (53)
Automation (7)
Bankruptcy (49)
Belgium (4)
Best Places to Work (1979)
BIO (2)
Biologics (9)
Biosimilars (85)
BioSpace Insights (11)
Biotechnology (6)
Bispecific (5)
Bladder cancer (39)
Brain cancer (20)
Breast cancer (68)
Cancer (886)
Cardiovascular disease (95)
Career advice (96)
Career pathing (1)
CAR-T (17)
CDC (11)
CDMO (17)
Cell therapy (64)
Cervical cancer (9)
Clinical research (9767)
Collaboration (287)
Commercialization (7)
Compensation (38)
Complete response letters (15)
COVID-19 (562)
CRISPR (24)
C-suite (201)
Cystic fibrosis (18)
Data (1233)
Denatured (1)
Depression (17)
Dermatology (35)
Diabetes (91)
Diagnostics (623)
Digital health (15)
Diversity, equity & inclusion (1)
Drug discovery (47)
Drug pricing (40)
Drug shortages (5)
Duchenne muscular dystrophy (41)
Earnings (13913)
Editorial (11)
Employer branding (2)
Employer resources (8)
ESMO (46)
Events (10501)
Executive appointments (170)
Eye disease (1)
FDA (3350)
Fibrodysplasia Ossificans Progressiva (6)
Fragile X (1)
Friedreich's ataxia (8)
Frontotemporal dementia (10)
Funding (275)
Gene editing (33)
Generative AI (10)
Gene therapy (66)
GLP-1 (163)
Government (1730)
Grass and pollen (2)
Guidances (77)
Healthcare (2308)
Hematology (17)
HIV (28)
Huntington's disease (9)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (5)
Immunology and inflammation (85)
Immuno-oncology (21)
Indications (64)
Infectious disease (660)
Inflammatory bowel disease (54)
Inflation Reduction Act (1)
Influenza (35)
Intellectual property (54)
Interviews (16)
IPO (2142)
IRA (6)
Job creations (468)
Job search strategy (91)
JPM (6)
Kidney cancer (6)
Kidney disease (15)
Labor market (6)
Layoffs (64)
Leadership (3)
Legal (837)
Licensing (9)
Liver cancer (16)
Longevity (2)
Lung cancer (130)
Lung diease (1)
Lymphoma (67)
Machine learning (7)
Management (3)
Manufacturing (154)
Marketing (3)
MASH (13)
Medical affairs (1)
Medical device (1790)
Medtech (1813)
Mergers & acquisitions (2832)
Metabolic disorders (191)
mRNA (62)
Multiple sclerosis (61)
Netherlands (6)
Neurodegenerative disease (56)
Neuropsychiatric disorders (16)
Neuroscience (444)
Neurotech (1)
NextGen: Class of 2026 (521)
Non-profit (536)
Now hiring (9)
Obesity (79)
Opinion (39)
Ovarian cancer (49)
Pain (27)
Pancreatic cancer (29)
Parkinson's disease (20)
Partnered (1)
Patents (111)
Patient recruitment (110)
Patient selection (9)
Peanut (12)
People (7269)
Peptides (3)
Pharmaceutical (2)
Pharmacy benefit managers (4)
Phase 1 (2092)
Phase 2 (3837)
Phase 3 (4541)
Pipeline (1962)
Policy (48)
Postmarket research (450)
Preclinical (691)
Press Release (2)
Prostate cancer (65)
Psychedelics (8)
Radioligand (1)
Radiopharmaceuticals (79)
Rare diseases (176)
Real estate (588)
Recruiting (5)
Regulatory (5045)
Reports (19)
Research institute (243)
Resumes & cover letters (14)
Rett syndrome (8)
RNA editing (2)
RSV (36)
Schizophrenia (23)
Series A (44)
Series B (40)
Service/supplier (3)
Sickle cell disease (11)
Special edition (7)
Spinal muscular atrophy (15)
Sponsored (4)
Startups (377)
Stomach cancer (2)
Substance use disorders (4)
Supply chain (19)
Tariffs (23)
The Weekly (26)
Vaccines (292)
Venture capital (24)
Weight loss (45)
Women's health (21)
Worklife (3)
Date
Last 7 days (100)
Last 30 days (339)
Last 365 days (3718)
2026 (3120)
2025 (3669)
2024 (4195)
2023 (4965)
2022 (10474)
2021 (10606)
2020 (9090)
2019 (6238)
2018 (5069)
2017 (4480)
2016 (3956)
2015 (4513)
2014 (3201)
2013 (2459)
2012 (2599)
2011 (2506)
2010 (2491)
Location
Africa (118)
Alabama (1)
Alaska (1)
Arizona (53)
Asia (3975)
Australia (947)
California (1319)
Canada (2289)
China (198)
Colorado (22)
Connecticut (37)
Delaware (45)
Europe (12700)
Florida (226)
Georgia (45)
Hawaii (1)
Idaho (6)
Illinois (85)
India (29)
Indiana (122)
Iowa (9)
Japan (106)
Kansas (8)
Kentucky (1)
Louisiana (9)
Maine (6)
Maryland (180)
Massachusetts (1089)
Michigan (23)
Minnesota (46)
Missouri (29)
Montana (1)
Nebraska (3)
Nevada (15)
New Hampshire (13)
New Jersey (751)
New York (514)
North Carolina (116)
North Dakota (1)
Northern California (716)
Ohio (35)
Oregon (6)
Pennsylvania (247)
Puerto Rico (1)
Rhode Island (2)
South America (162)
South Carolina (2)
Southern California (536)
Tennessee (8)
Texas (199)
United States (5213)
Utah (25)
Vermont (1)
Virginia (23)
Washington D.C. (1)
Washington State (68)
Wisconsin (3)
Wyoming (1)
94,253 Results for "sanofi aventis canada".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sanofi inaugurates new flu vaccine facility, Canada’s largest biomanufacturing investment
September 16, 2026
·
5 min read
Manufacturing
Sanofi breaks ground on insulin plant after securing German government support
The European Commission approved Germany’s financial support after assessing the risks of Sanofi stopping insulin API production at the Frankfurt campus.
October 19, 2026
·
2 min read
·
Nick Paul Taylor
Earnings
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported third-quarter earnings.
October 30, 2026
·
2 min read
·
Nick Paul Taylor
Immunology and inflammation
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupixent.
October 1, 2026
·
3 min read
·
Tristan Manalac
Business
Sanofi’s R&D head exits, with AI biotech Xaira’s exec stepping in
About two months into CEO Belén Garijo’s new tenure, Sanofi’s R&D chief has departed, with Xaira’s chief medical officer set to take charge of the pharma’s pipeline.
June 22, 2026
·
1 min read
·
Gabrielle Masson
Press Releases
/C O R R E C T I O N -- Sanofi-Aventis Canada Inc./
October 21, 2025
·
8 min read
Drug Development
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
Sanofi had hoped the acquisition of Kymab would fill a major hole that will be left as autoimmune juggernaut Dupixent heads toward a patent cliff. Now, another therapy has failed to meet expectations.
July 24, 2026
·
3 min read
·
Gabrielle Masson
Earnings
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
Sanofi is going to “look very deeply” at its late-stage pipeline as part of a portfolio prioritization initiative, though new CEO Belén Garijo didn’t commit to shelving a specific number of assets.
July 30, 2026
·
2 min read
·
Tristan Manalac
Pipeline
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
Since stepping in as Sanofi’s CEO in April, Belén Garijo has launched a deep look at the pharma’s pipeline, reassessing assets based on “scientific merit” and potential for long-term value in the quest for a Dupixent follow-up.
August 6, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy
The discontinuation of Sanofi’s Phase 3 study for its complement inhibitor drug in chronic inflammatory demyelinating polyneuropathy delivers an ‘obviously disappointing’ blow to the broader drug class, according to William Blair.
June 10, 2026
·
2 min read
·
Tristan Manalac
1 of 9,426
Next
